3SBio (STU:83B) EBITDA: €1,376 Mil (TTM As of Dec. 2025)


STU:83B 3SBio Inc STU:83B
90 GF Score
Price €1.70
GF Value €1.51
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is 3SBio EBITDA?

3SBio STU:83B -1.38% 90 EBITDA is €1,376 Mil as of Dec. 2025. GuruFocus rates STU:83B with a GF Score™ of 90/100 and a GF Value™ of €1.51 (Modestly Overvalued). The stock has 1 warning sign investors should review.

3SBio's EBITDA for the six months ended in Dec. 2025 was €1,145 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1,376 Mil.

During the past 12 months, the average EBITDA Growth Rate of 3SBio was 255.60% per year. During the past 3 years, the average EBITDA Growth Rate was 59.80% per year. During the past 5 years, the average EBITDA Growth Rate was 35.60% per year. During the past 10 years, the average EBITDA Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 12 years, the highest 3-Year average EBITDA Growth Rate of 3SBio was 59.80% per year. The lowest was -1.50% per year. And the median was 17.90% per year.

3SBio's EBITDA per Share for the six months ended in Dec. 2025 was €0.46. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.56.

During the past 12 months, the average EBITDA per Share Growth Rate of 3SBio was 255.80% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 63.60% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 39.40% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 12 years, the highest 3-Year average EBITDA per Share Growth Rate of 3SBio was 63.60% per year. The lowest was -2.70% per year. And the median was 16.70% per year.

3SBio  (STU:83B) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


3SBio EBITDA Related Terms


3SBio EBITDA Historical Data

* Premium members only.

The historical data trend for 3SBio's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3SBio EBITDA Chart

3SBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 314.62 372.65 324.36 433.37 1,376.80

3SBio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 137.54 219.44 208.59 230.54 1,145.29

STU:83B vs VRTX, REGN, ALNY: EBITDA Comparison

For the Biotechnology subindustry, 3SBio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3SBio EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where 3SBio's EV-to-EBITDA falls into.


STU:83B
90GF Score
3SBio Inc STU:83B
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

3SBio's EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

3SBio's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2025, 3SBio's EBITDA was €1,377 Mil.

3SBio's EBITDA for the quarter that ended in Dec. 2025 is calculated as

3SBio's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2025, 3SBio's EBITDA was €1,145 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1,376 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of €1,376 Mil mean?
3SBio (STU:83B) has a EBITDA of €1,376 Mil as of Dec. 2025. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on 3SBio.
Is 3SBio's EBITDA too high?
3SBio's current EBITDA is €1,376 Mil. Overall, 3SBio has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's EBITDA compare to VRTX and REGN?
3SBio's EBITDA of €1,376 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Biotechnology company?
A good EBITDA depends on the Biotechnology industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on 3SBio. 3SBio's current EBITDA is €1,376 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.51, compared to a current price of €1.70 — trading 12.9% above its estimated fair value. The current EBITDA is €1,376 Mil. 3SBio's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For 3SBio (STU:83B), the current EBITDA is €1,376 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3SBio (STU:83B) Overvalued in 2026?

Based on GuruFocus' analysis, 3SBio stock appears to be overvalued. The current stock price of €1.70 is trading 12.9% above its estimated GF Value™ of €1.51. GuruFocus considers 3SBio to be Modestly Overvalued.

Key valuation signals for STU:83B:

  • EBITDA: €1,376 Mil
  • GF Value™: €1.51 vs. price of €1.70 (12.9% above fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


3SBio Business Description

Other Exchanges TRSBF:USA01530:Hong Kong
Address No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
90GF Score

Get the complete analysis for STU:83B

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.70
Price
€1.51
GF Value